1427357-47-8

Basic information

• Product Name: 3-fluoro-4-methoxypicolinonitrile
• Synonyms: 3-fluoro-4-methoxypicolinonitrile;3-Fluoro-4-methoxy-pyridine-2-carbonitrile
• CAS NO: 1427357-47-8
• Molecular Formula: C7H5FN2O
• Molecular Weight: 152.13
• EINECS: -0
• Mol File: 1427357-47-8.mol

Chemical Properties

• Boiling Point: 248.5±40.0 °C(Predicted)
• Appearance: /
• Density: 1.26±0.1 g/cm3(Predicted)
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: -1.44±0.18(Predicted)
• CAS DataBase Reference: 3-fluoro-4-methoxypicolinonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: 3-fluoro-4-methoxypicolinonitrile(1427357-47-8)
• EPA Substance Registry System: 3-fluoro-4-methoxypicolinonitrile(1427357-47-8)

Safety Data

• Hazardous Substances Data: 1427357-47-8(Hazardous Substances Data)

Upstream product

• 7677-24-9 trimethylsilyl cyanide 
• 1060805-03-9 3-fluoro-4-methoxypyridine 
• 109613-98-1 2-bromo-3-fluoro-4-methoxypyridine 

Relevant articles and documents

PLASMA KALLIKREIN INHIBITORS AND USES THEREOF

The present invention provides compounds and compositions thereof which are useful as inhibitors of plasma kallikrein and which exhibit desirable characteristics for the same.

TREATMENTS OF HEREDITARY ANGIOEDEMA

The present invention relates to treatments of hereditary angioedema (HAE). In particular, the present invention provides on-demand treatments of hereditary angioedema (HAE) by orally administering a plasma kallikrein inhibitor to a patient in need thereo

TREATMENTS OF ANGIOEDEMA

The present invention relates to treatments of angioedema, and specifically bradykinin-mediated angioedema non-hereditary (BK-AEnH). In particular, the present invention provides on-demand treatments of bradykinin-mediated angioedema non-hereditary (BK-AE

SOLID FORMS OF A PLASMA KALLIKREIN INHIBITOR AND SALTS THEREOF

New solid forms of the plasma kallikrein inhibitor, 1‐({4‐[(5‐fluoro‐2‐oxopyridin‐1‐ yl)methyl]phenyl}methyl)‐N‐[(3‐fluoro‐4‐methoxypyridin‐2‐yl)methyl]‐3‐(methoxymethyl)pyrazole‐4‐ carboxamide and its salts, are described.

DOSAGE FORMS COMPRISING A PLASMA KALLIKREIN INHIBITOR

The present inventionrelates tooral solid dosage forms comprising a plasma kallikrein inhibitor, in particular a solid form (Form 1) of the compoundof Formula A. Also provided are methods of preparing oral solid dosage forms comprising the compound of For

SOLID FORMS OF A PLASMA KALLIKREIN INHIBITOR AND SALTS THEREOF

The present invention relates to new solid forms of a plasma kallikrein inhibitor, a pharmaceutical composition containing them and their use in therapy. Also provided are processes for preparing the solid forms of the present invention.

PYRAZOLE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS

The present invention provides a selection of compounds of formula (I): (I) compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activ

POLYMORPHS OF N-[(3-FLUORO-4-METHOXYPYRIDIN-2-YL)METHYL]-3-(METHOXYMETHYL)-1 -({4-[2-OXOPYRIDIN-1 -YL)METHYL]PHENYL} METHYL) PYRAZOLE -4-CARBOXAMIDE AS KALLIKREIN INHIBITORS

The invention provides new polymorphs of N-[(3-fluoro-4- methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-l-({4-[(2- oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide and salts thereof, pharmaceutical compositions containing them and their use as k

N-((HET)ARYLMETHYL)-HETEROARYL-CARBOXAMIDES COMPOUNDS AS PLASMA KALLIKREIN INHIBITORS,

The present invention provides compounds of formula (I): (I) compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicat